University Of Pecs
- Address
- lock Available on a paid plan
Neoplasms and Hematologic Oncology at University Of Pecs
Research at the Department of pediatrics focuses on acute lymphoblastic leukemia, with an emphasis on improving outcomes for infants and other pediatric patients affected by this serious cancer. The trials in this area are aimed at testing better treatment strategies and strengthening long-term disease control.
- Improving event-free survival for infants with newly diagnosed acute lymphoblastic leukemia
- Evaluating treatment effectiveness in high-risk pediatric blood cancer care
- Advancing care for infant leukemia through clinically focused research
This work reflects a strong commitment to pediatric cancer research at University Of Pecs, with the goal of helping clinicians achieve better outcomes for young patients.
Diagnostic Imaging and Contrast-Enhanced MRI
Another major research area at the site involves analytical, diagnostic and therapeutic techniques and equipment, especially studies related to contrast enhancement in magnetic resonance imaging in children. These trials are designed to improve the understanding of imaging agents and support safer, more effective diagnostic evaluation in pediatric care.
- Studying contrast-enhanced MRI in children undergoing diagnostic imaging
- Assessing how imaging agents behave in the body to support safer use
- Improving diagnostic tools for pediatric patients at University Of Pecs
The research helps expand knowledge of pediatric imaging and supports better diagnostic decision-making for children across a range of clinical settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 26 therapeutic areas and 15 of 343 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 339 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 56 by active trials.
- 1AstraZeneca AB9active
lock +55 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG17trials
lock +28 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Pecs
lock Showing 1 of 195 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 343 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 16 | Unknown | 2018-12-27 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.